Treatment of patients with severe and moderate acne

Cover Page

Cite item


Objective. To determine the effectiveness and safety ot the drug Sotret when treating patients with severe or moderate acne resistant to other therapies. Material and methods. The study included 30 people. Determining the severity ot acne was conducted using the DIA, the assessment ot quality ot lite - the scale ot CADI. In the acne treatment patients were using the drug Sotret as monotherapy. Results of the study. Sortret drug therapy contributed to erase the severe and rapid dynamics ot indicators DIA, the tormation ot clinical remission was reported in 93.33% ot patients. Adverse events were dose dependent and primarily recorded in the tirst three months ot the treatment. Use ot the drug by patients erase acne contributed to improving the quality ot lite at an average degree ot severity ot the disease at 93.53%, with a heavy - at 82.74%. Conclusion. The clinical etticacy expressed Sotret demonstrates its wide application

About the authors

YU. N. Perlamutrov

Moscow State University üt Medicine and Dentistry

Author for correspondence.
Russian Federation

K. B. Olhovskaya

Moscow State University üt Medicine and Dentistry

Russian Federation


  1. Gollnick H., Zouboulis C.C. Not all acne is acne vulgaris. Dtsch Ärztebl Int 2014; 111 (17): 301-312.
  2. Bhate K., Williams H.C. Epidemiology of acne vulgaris. Br J Dermatol 2013; 168: 474-485.
  3. Silverberg J.I., Silverberg N.B. Epidemiology and extracutaneous comorbidities of severe acne in adolescence: a U.S. population based study. Br J Dermatol 2014; 170: 1136-1142.
  4. Thiboutot D. New treatments and therapeutic strategies for acne Arch Fam Med 2000; 9 (2): 179-186.
  5. Zouboulis C.C. Acne as a chronic systemic disease. Clin Dermatol 2014; 32: 389-396.
  6. Kungurov N.V., Kokhan M.M., Zil'berberg N.V. i soavt. Terapiya bol'nykh akne i postakne: [metod. rekomendatsii] Ekaterinburg, 2013, 52 s. [Кунгуров Н.В., Кохан М.М., Зильберберг Н.В. и соавт. Терапия больных акне и постакне: [метод. рекомендации] Екатеринбург, 2013; 52.]
  7. Navarini A.A., Simpson M.A., Weale M. et al. Genome-wide association study identifies three novel susceptibility loci for severe acne vulgaris. Nat Commun 2014; 5: 4020.
  8. Zhang M., Qureshi A.A., Hunter D.J., Han J. A genome-wide association study of severe teenage acne in European Americans. Hum Genet 2014; 133 (3): 259-264.
  9. Chalmers R.L. The evidence for the role of transforming growth factor-beta in the formation of abnormal scarring. Int Wound J 2011; 8 (3): 218-223.
  10. Tan J.K., Tang J., Fung K. et al. Development and validation of a comprehensive acne severity scale. J Cutan Med Surg 2007; 11 (6): 211-216.
  11. Leyden J.J. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49: 211-217.
  12. Perlamutrov Yu.N., Olkhovskaya K.B., Isaeva S.G. Current aspects of external acne treatment pathophysiology. Plastic Surgery and Cosmetology 2012. 3: 461-463. [Перламутров Ю.Н., Ольховская К.Б., Исаева С.Г. Современные аспекты патофизиологии наружной терапии акне. Пластическая хирургия и косметология 2012 (3): 461-463.]
  13. Nast A., Dreno B., Bettoli V. et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 1): 1-29.
  14. Ghalamkarpour F., Nasiri S. Isotretinoin in treatment of acne: its efficacy, side effects, and recurrence rate of disease. Arch Iran Med 2006; 9 (3): 228-230.
  15. Zouboulis C.C., Piquero-Matin J. Update and future of systemic acne treatment. Dermatology 2003; 206: 37-53.
  16. Peck G.L., Olsen T.G., Butkus D. et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6: 735-745.
  17. Strauss J.S., Leyden J.J., Lucky A.W. et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001; 45: 187-195.
  18. Jones D.H., King K., Miller A.J., Cunliffe W.J. A dose-response study of 13-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108: 333-343.
  19. Tan J., Humphrey S., Vender R.A. et al. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014; 171: 1508-1516.
  20. Layton A.M., Dreno B., Gollnick H.P.M., Zouboulis C.C. A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 773-776.
  21. Zouboulis C.C. The truth behind this undeniable efficacy - recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99-100.
  22. Maloney M.E., Stone S.P. Isotretinoin and iPledge: a view of results. J Am Acad Dermatol 2011; 65: 418-419.
  23. Zane L.T., Leyden W.A., Marqueling A.L., Manos M.M. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006; 142: 1016-1022.
  24. Alhusayen R.O., Juurlink D.N., Mamdani M.M. et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2013; 133: 907-912.
  25. Kokhan M.M., Keniksfest Iu.V., Shaîbakova Iu.B. et al. Experience of treating patients with various forms of acne using systemic isotretinoin. Clin Dermatol and Venerol 2014; 12 (2); 91-99. [Кохан М.М., Кениксфест Ю.В., Шайбакова Ю.Б. и соавт. Опыт терапии больных различными формами акне препаратом системного изотретиноина. Клин дерматол и венерол 2014; 12 (2); 91-99.]
  26. Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat'ev D. Dermatologicheskiy indeks akne. Esteticheskaya meditsina. 2004; 3 (1): 62-65. [Кочергин Н.А., Самгин М.А., Монахов С.А., Игнатьев Д. Дерматологический индекс акне. Эстетическая медицина 2004; 3 (1): 62-65.]
  27. Motley R.J., Finlay A.Y. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol 1992; 17: 1-3.

Copyright (c) 2015 Perlamutrov Y.N., Olhovskaya K.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies